Low-grade prostate cancer may not require aggressive treatment

Key points
- Most men diagnosed with low-grade prostate cancer may not need radical treatments such as surgery or radiotherapy, which can have serious side effects, British researchers said on Thursday.
- A modeling study by scientists at the Institute of Cancer Research in England has shown that men whose cancer is detected early with a screening test are unlikely to die from the illness.
- So treatments, such as surgery to remove the prostate gland or radiotherapy, which can cause incontinence and impotence will probably not improve their survival.
- "Most men with prostate cancer detected by PSA screening will live out their natural span without the disease causing them any ill effects," said Dr Chris Parker whose findings are reported in the British Journal of Cancer.
Most men diagnosed with low-grade prostate cancer may not need radical treatments such as surgery or radiotherapy, which can have serious side effects, British researchers said on Thursday.
A modeling study by scientists at the Institute of Cancer Research in England has shown that men whose cancer is detected early with a screening test are unlikely to die from the illness.
So treatments, such as surgery to remove the prostate gland or radiotherapy, which can cause incontinence and impotence will probably not improve their survival.
"Most men with prostate cancer detected by PSA screening will live out their natural span without the disease causing them any ill effects," said Dr Chris Parker whose findings are reported in the British Journal of Cancer.
"The decision whether to have radical treatment can be tremendously difficult for the patients," he added.
The modeling study predicted that the chance a man aged 55-59 with a low-grade cancer dying of the disease within 15 years, even without treatment, is about one in a 100.
But the research suggests that men with high-grade advanced cancer would benefit from treatments such as surgery or radiotherapy.
The PSA test measures levels of a protein called prostate-specific antigen, which is produced by the prostate gland, in the blood. It has enabled doctors to detect the cancer much earlier than they previously could.
Parker and his team are testing a new prostate cancer management technique called Active Surveillance, which aims to target treatment only to men who need it.
"Patients are closely monitored and the choice between radical treatment and continued observation is based on evidence of disease progressions," he explained.
Prostate is one of the most common cancers in men. Each year 543,000 new cases are reported worldwide. The disease kills 200,000 mostly older men in developed countries, according to the International Agency for Research on Cancer.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
GuideEarly Prostate Cancer Cases Fall Along With Screening
Fewer men are being screened for prostate cancer, and fewer early-stage cases are being detected, according to two studies published Tuesday in The Journal of the American Medical Association. The number of cases has…
19 December 2015
NewsNon-Invasive Robotic Surgery Destroys Prostate Cancer Tumors
Prostate cancer is the most common cancer in American men and is the fifth-leading cause of cancer death in men globally. While death rates for prostate cancer have been decreasing in most developed countries, mortality…
18 December 2015
NewsNew Model for Prostate Cancer Screening Reduces Biopsies
A new model for prostate cancer screening can significantly reduce the number of unnecessary biopsies and minimize detection of clinically insignificant disease in comparison with standard screening using prostate…
24 November 2015





